Aging Population & Rising Incidence of Chronic Diseases to Drive the Global Mesenchymal Stem Cells Market, According to New Report by Global Industry Analysts, Inc.

GIA announces the release of a comprehensive global report on Mesenchymal Stem Cells (MSCs) markets. Global market for Mesenchymal Stem Cells (MSCs) is projected to exceed US$4.8 billion by 2018, driven by growing demand for mesenchymal stem cell based therapies for age related and chronic diseases.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Mesenchymal Stem Cells (MSCs): A Global Strategic Business Report

San Jose, California (PRWEB) January 13, 2014

Follow us on LinkedIn – Stem Cells represent one of the most rapidly growing areas of biotechnology, and investors are currently injecting money into the development of stem cell therapies for a broad range of hard-to-treat diseases. The adult stem cells market is huge compared to cord blood and embryonic stem cell markets. Implementation of various governmental regulations is expected to drive growth in stem cell research over the coming years. The economic and medical potential of stem cell research is encouraging huge investments in the sector by governments, as well as pharmaceutical and biotechnology companies.

The use of human cells as clinical therapies for the treatment of various diseases has undergone a dramatic expansion in the last few years, thus leading to the development of a new branch in medical science – regenerative medicine. Regenerative medicine is a science that involves introduction of cells into the human body with the aim of replacing diseased or dying cells with healthy ones. A plethora of information pertaining to the biology and differentiation potential of Mesenchymal Stem Cells is available, and several thousands of publications have thrown light on the heterogenic nature of the MSC population, depending on species, donor and source tissue characteristics. Thus, MSCs represent one of the most promising systems for cell therapy due to their partial ability to ape embryonic stem cells, and other advantages associated with ethical implications, expandability, availability, and transplantability.

Mesenchymal Stem Cells, mainly found in the bone marrow, are multipotent stem cells that can differentiate into various cell types, including chondrocytes, osteoblasts, myocytes, beta-pancreatic islets cells, adipocytes, and even neuronal cells. In addition to their ability to differentiate into various cell types, MSCs are associated with a large number of benefits, such as easy acquisition and isolation, rapid ex vivo expansion, ease of autologous transplantation and superior paracrine function. MSCs thus represent a population of cells with potential to cure a wide range of degenerative and acute diseases and injuries.

Aging population and rise in age-related health ailments, especially those related to the heart and bone is driving demand for convenient, efficient and painless therapies. The ability of MSCs to regenerate and repair cartilages and bone tissues is being exploited for development of therapeutic procedures for various bone related diseases and injuries. MSCs are also being viewed as a potential substitute to knee replacement surgeries and other operative procedures such as those requiring correction of the knee meniscus. These therapies would be of special interest to ageing demographics, as MSC therapies help lower the risk of complications, pain and discomfort associated with conventional invasive surgical procedures.

As stated by the new market research report on Mesenchymal Stem Cells, the United States represents the largest market worldwide. Asia-Pacific represents the market with the highest growth potential. Growth in the region is led by growing healthcare spends, rising life expectancies and growing incidence of chronic diseases.

Key players covered in the report include Aastrom Biosciences Inc, Advanced Cell Technology Incorporated, Anterogen Co Ltd., Athersys Inc., Cell Applications Inc., Celprogen Inc., Cyagen Biosciences Inc., EMD Millipore Corporation, Genlantis Inc., K-Stecmcell Co Ltd., Life Technologies Corporation, Lonza Group, Medipost Co Ltd., Mesoblast Limited, Neuromics, NuVasive® Inc., Orthofix International N.V., Osiris Therapeutics Inc., Pharmicell Co Ltd., PromoCell GmbH, R&D Systems Inc., ScienCell Research Laboratories, Stemcell Technologies Inc., Stemedica Cell Technologies Inc., StemGenesis, Stempeutics Research Pvt Ltd., TiGenix NV, Trevigen Inc., and Vitro Biopharma, among others.

The research report titled "Mesenchymal Stem Cells (MSCs): A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of the market, industry overview, trends, growth drivers, latest product launches and recent industry activity. The report provides market estimates and projections in US dollars for major geographic markets including the United States, Canada, Japan, Europe, Asia-Pacific, and Rest of World.

For more details about this comprehensive market research report, please visit –
http://www.strategyr.com/Mesenchymal_Stem_Cells_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

###


Contact

Attachments